Upper Gastro Intestinal Surgery, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Sharoe Green Lane North, Fulwood, Preston, Lancashire, PR2 9HT, UK.
Department of Oncology, University Hospital Santa Maria della Misericordia, Piazzale della Misericordia 13, 33100, Udine, Italy.
Support Care Cancer. 2019 Dec;27(12):4607-4613. doi: 10.1007/s00520-019-04769-2. Epub 2019 Apr 1.
Taste disorders are one of the most common side effects of treatment in oncology patients and often occur after allogeneic haematopoietic cell transplantation (allo-HCT). Dysgeusia does not receive close medical attention, and information about this disorder is largely based on the clinician's own experience. However, taste disorders can have an impact on the quality of life and nutritional status of survivors of allo-HCT. The number of performed annual transplantations is growing, as the number of older long-term survivors increases, but only few research studies examine survivors of allo-HCT with taste disorders. We conducted a qualitative descriptive study to explore experiences of dysgeusia in patients undergoing allo-HCT and to examine what strategies they used to mitigate it.
Using purposeful sampling, survivors of allo-HCT were recruited. Audiotape interviews were conducted until data saturation was achieved. Each interview was transcribed verbatim, and content analyses were performed to extract significant themes and subthemes.
Three major themes embracing various aspects of allo-HCT survivors' experiences were identified: (1) the shape of taste; (2) everything is irritating and it is arduous to eat; (3) finding new strategies to overcome the problems. Together, they highlight the experiences of survivors showing how the taste disorders can affect the physical, psychological and social dimensions of a person.
A cumulative burden is the result of dysgeusia and its clinical course reinforced also by related symptoms. Healthcare professionals must focus their attention on the management of these symptoms and offer interventions to safeguard the patient's social, physical and psychological well-being.
味觉障碍是肿瘤患者治疗中最常见的副作用之一,通常发生在异基因造血细胞移植(allo-HCT)之后。味觉障碍并未引起密切的医学关注,关于这种疾病的信息在很大程度上基于临床医生的自身经验。然而,味觉障碍会对 allo-HCT 幸存者的生活质量和营养状况产生影响。由于老年长期幸存者人数的增加,每年进行的移植数量不断增加,但只有少数研究调查了 allo-HCT 后有味觉障碍的幸存者。我们进行了一项定性描述性研究,以探讨 allo-HCT 患者味觉障碍的体验,并研究他们用来减轻味觉障碍的策略。
采用目的性抽样,招募 allo-HCT 幸存者。进行录音访谈,直到达到数据饱和。逐字转录每次访谈,并进行内容分析以提取重要主题和子主题。
确定了三个主要主题,涵盖了 allo-HCT 幸存者体验的各个方面:(1)味觉的形状;(2)一切都令人刺激,难以进食;(3)寻找克服问题的新策略。这些主题共同凸显了幸存者的体验,展示了味觉障碍如何影响人的身体、心理和社会层面。
味觉障碍及其临床病程的累积负担也因相关症状而加重。医疗保健专业人员必须关注这些症状的管理,并提供干预措施,以保障患者的社会、身体和心理健康。